TENAX THERAPEUTICS INC
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
TENX$1.69-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following exhibits are being filed or furnished as part of this Quarterly Report on Form 10-Q and are numbered in accordance with Item 601 of Regulation S-K:
| Exhibit Number | Description |
| 3.1.1 | Certificate of Incorporation of Oxygen Biotherapeutics, Inc., dated April 17, 2008 (incorporated herein by reference to Exhibit 3.01 to our Current Report on Form 8-K filed with the SEC on June 30, 2008). |
| 3.1.2 | Certificate of Amendment of the Certificate of Incorporation, effective November 9, 2009 (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the SEC on November 13, 2009). |
| 3.1.3 | Certificate of Amendment of the Certificate of Incorporation, effective May 10, 2013 (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the SEC on May 15, 2013). |
| 3.1.4 | Certificate of Amendment of the Certificate of Incorporation, effective September 19, 2014 (incorporated herein by reference to Exhibit 3.4 to our Quarterly Report on Form 10-Q filed with the SEC on December 15, 2014). |
| 3.1.5 | Certificate of Amendment of the Certificate of Incorporation, effective February 23, 2018 (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the SEC on February 23, 2018). |
| 3.1.6 | Certificate of Amendment to Certificate of Incorporation, as amended of Tenax Therapeutics, Inc., effective January 4, 2023 (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the SEC on January 4, 2023). |
| 3.1.7 | Certificate of Amendment of Certificate of Incorporation of Tenax Therapeutics, Inc. (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the SEC on January 5, 2024). |
| 3.2 | Certificate of Designation of Series A Convertible Preferred Stock, dated December 10, 2018 (incorporated herein by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on December 11, 2018). |
| 3.3 | Certificate of Designation of Series B Convertible Preferred Stock, dated January 15, 2021 (incorporated herein by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on January 19, 2021). |
| 4.1 | Warrant Agency Agreement, dated as of February 12, 2024, by and between Tenax Therapeutics, Inc. and Direct Transfer LLC (incorporated herein by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the SEC on February 12, 2024). |
| 4.2 | Form of February 2024 Pre-Funded Common Stock Purchase Warrant (incorporated herein by reference to Exhibit 4.2 to our Current Report on Form 8-K filed with the SEC on February 12, 2024). |
| 4.3 | Form of February 2024 Common Stock Purchase Warrant. (incorporated herein by reference to Exhibit 4.3 to our Current Report on Form 8-K filed with the SEC on February 12, 2024). |
| 10.1 | Placement Agency Agreement, dated as of February 8, 2024, by and between Tenax Therapeutics, Inc. and Roth Capital Partners, LLC (incorporated herein by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on February 12, 2024). |
| 10.2 | Form of Securities Purchase Agreement by and between Tenax Therapeutics, Inc. and the purchasers named therein (incorporated herein by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the SEC on February 12, 2024). |
| 10.3+ | Amendment to the License Agreement of September 20, 2013 by and between Tenax Therapeutics, Inc. and Orion Corporation, dated as of February 19, 2024 (incorporated herein by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on February 20, 2024). |
| 31.1* | Certification of President and Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002. |
| 31.2* | Certification of Interim Chief Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002. |
| 32.1** | Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2** | Certification of Interim Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101* | Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q. |
| 104* | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set. |
- Filed herewith
** Furnished herewith
- Portions of this Exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company agrees to furnish supplementally an unredacted copy of this Exhibit to the SEC upon request.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.